Metrics as of 10/14/2026, 08:17 AM (Berlin time), refresh in progress.
Cannara Biotech Stock
Cannara Biotech Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- Zohar Krivorot
- Employees
- 452
- Market cap
- $206 M
- IPO
- 14/01/2019
- Web
- cannara.ca
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio…
Cannara Biotech stock: price history
1D
+2.5%
1W
+0.5%
1M
+5.0%
6M
+17.4%
YTD
+20.1%
1Y
+22.2%
2Y
+226.6%
5Y
+39.3%
10Y
–
Next earnings date
Next earnings date
23/11/2026 (in 37 days)
Volatility around earnings
~37% stronger price swings than usual
Ask the agents about Cannara Biotech
Cannara Biotech stock metrics
P/E
18.4
P/B
1.64
EV/EBITDA
14.41
RETURN ON EQUITY
3.8%
NET MARGIN
15.2%
DEBT/EQUITY
0.29
DIVIDEND YIELD
0.0%
AS OF
31/05/2026
Free float & liquidity
FREE FLOAT
45.8%
FLOAT SHARES
45,210,613
AVG. DAILY VOLUME (30D)
45,710
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cannara Biotech stock
What does Cannara Biotech do?
Cannara Biotech Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Zohar Krivorot, the company employs around 452 people.
The IPO was on 14/01/2019; the stock trades on TSX under the ticker LOVE.TO.
When does Cannara Biotech report next?
The next earnings date is 23/11/2026.
Around past earnings, price swings were roughly 37% stronger than usual.
Does Cannara Biotech pay a dividend?
No, Cannara Biotech currently does not pay a dividend.
Which stocks are comparable to Cannara Biotech?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Cannara Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cannara Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.